Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bexsero + Menveo
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This refers to the concomitant administration of two distinct meningococcal vaccines, Bexsero (4CMenB) and Menveo (ACWY-CRM), as evaluated in a Phase II clinical trial led by Prof. Elizabeth Miller at Public Health England. Bexsero is a multicomponent vaccine designed to protect against serogroup B *Neisseria meningitidis*, containing four main antigens: factor H binding protein (fHbp), neisserial adhesin A (NadA), neisserial heparin binding antigen (NHBA), and porin A (PorA P1.4) in an outer membrane vesicle. Menveo is a quadrivalent conjugate vaccine targeting serogroups A, C, W-135, and Y, utilizing the CRM197 carrier protein. The combination is intended to provide broad protection against invasive meningococcal disease, particularly for individuals at high occupational risk, such as laboratory workers.
- Brand names
- BexseroMenveo
- Other names
- meningococcal B vaccine + meningococcal ACYW conjugate vaccineMenB + MenACWYfour-component meningococcal group B vaccinequadrivalent meningococcal group ACWY conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)fHbp (Factor H-binding protein)NHBA (Neisserial heparin-binding antigen)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)PorACFH (Complement factor H)
Beyond the preview
Go deeper on Bexsero + Menveo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bexsero + Menveo.